Ingredient in pre-clinical treatment for retinal neovascular disease targets gene associated with acute myeloid leukaemia
An active ingredient in eye drops that were being developed for the treatment of a form of eye disease has shown promise for treating an aggressive form of blood cancer. Scientists at the Wellcome Sanger Institute, University of Cambridge, University of Nottingham and their collaborators have found that this compound, which targets an essential cancer gene, could kill leukaemia cells without harming non-leukemic blood cells.
The results, published today (19 December) in Nature Communications reveal a potential new treatment approach for an aggressive blood cancer with a poor prognosis.
Acute myeloid leukaemia (AML) is a form of blood cancer that affects people of all ages, often requiring months of intensive chemotherapy and prolonged hospital admissions. It develops in cells in the bone marrow crowding out the healthy cells, in turn leading to life-threatening infections and bleeding.
Mainstream AML treatments have remained unchanged for over 30 years, with the current treatment being chemotherapy, and the majority of people’s cancer cannot be cured. A subtype of AML, driven by rearrangements in the MLL gene has a particularly bad prognosis.
In a previous study, researchers at the Sanger Institute developed an approach, based on CRISPR gene editing technology, which helped them identify more than 400 genes as possible therapeutic targets for different subtypes of AML. One of the genes, SRPK1, was found to be essential for the growth of MLL-rearranged AML. SRPK1 is involved in a process called RNA splicing, which prepares RNA for translation into proteins, the molecules that conduct the majority of normal cellular processes, including growth and proliferation.
In a new study, Sanger Institute researchers and their collaborators set out to work out how inhibition of SRPK1 can kill AML cells and whether it has therapeutic potential in this disease. They first showed that genetic disruption of SRPK1 stopped the growth of MLL-rearranged AML cells and then went on to study the compound SPHINX31, an inhibitor of SRPK1, which was being used to develop an eye drop treatment for retinal neovascular disease – the growth of new blood vessels on the retinal surface that bleed spontaneously and cause vision loss.
The team found that the compound strongly inhibited the growth of several MLL-rearranged AML cell lines, but did not inhibit the growth of normal blood stem cells. They then transplanted patient-derived human AML cells into immunocompromised mice and treated them with the compound. Strikingly, the growth of AML cells was strongly inhibited and the mice did not show any noticeable side effects.
“We have discovered that inhibiting a key gene with a compound being developed for an eye condition can stop the growth of an aggressive form of acute myeloid leukaemia without harming healthy cells. This shows promise as a potential approach for treating this aggressive leukaemia in humans.”
Dr George Vassiliou, joint leader of the research from the Wellcome Sanger Institute and the Wellcome-MRC Cambridge Stem Cell Institute
SRPK1 controls the splicing* of RNA in the production of new proteins. An example of a gene that is affected when SRPK1 is blocked is BRD4, a well-known gene that maintains AML. Inhibiting SRPK1 causes the main form of BRD4 to switch to another form, a change that is detrimental to AML growth.
“Our study describes a novel mechanism required for leukaemia cell survival and highlights the therapeutic potential of SRPK1 inhibition in an aggressive type of AML. Targeting this mechanism may be effective in other cancers where BRD4 and SRPK1 play a role, such as metastatic breast cancer.”
Dr Konstantinos Tzelepis, joint lead author from the Wellcome Sanger Institute and University of Cambridge
“When Dr Vassiliou told me that SRPK1 was required for the survival of a form of AML, I immediately wanted to work with him to find out if our inhibitors could actually stop the leukaemia cells growing. The fact that the compound worked so effectively bodes well for its potential development as a new therapy for leukaemia. It will take some time, but there is real promise for a new treatment on the horizon for patients with this aggressive cancer.”
Professor David Bates, from the University of Nottingham and co-founder of biotech company Exonate, which develops eye drops for retinal diseases
Learn more: From eye drops to potential leukaemia treatment
The Latest on: Acute myeloid leukaemia
via Google News
The Latest on: Acute myeloid leukaemia
- Leukaemia patient waited 12 hours in A&E before deathon October 7, 2020 at 10:09 pm
A patient with leukaemia and another who was terminally ill were made to wait at least 12 hours in A&E before they later died.
- Hemogenyx Pharmaceuticals PLC Announces SAFE-HEMO-CAR-T Effective against AML in vitroon October 5, 2020 at 11:00 pm
LONDON, UK / ACCESSWIRE / October 6, 2020 / Hemogenyx Pharmaceuticals plc (LSE:HEMO), the biopharmaceutical group developing new therapies and treatments for blood diseases, is pleased to announce the ...
- A Uniquely Patient-Focused Take on Treating AML in Older Adultson October 5, 2020 at 1:55 pm
Dr Mikkael Sekeres discusses how the recent ASH guidelines, on which he is a coauthor, are meant to guide the difficult decisions that follow a new diagnosis of AML in older patients.
- Kronos Bio Seeks $175 Million IPO For AML And Solid Tumor Treatmentson October 5, 2020 at 12:43 pm
Kronos Bio has filed proposed terms for a $175 million U.S. IPO. The firm is advancing a pipeline of treatment candidates for acute myeloid leukemia [AML] and solid tumors. KRON has shown intriguing ...
- Fatal Invasive Pulmonary Aspergillosis in COVID-19 Patient with Acute Myeloid Leukemia in Iran.on October 4, 2020 at 10:13 pm
Although patients with severe immunodeficiency and hematological malignancies has been considered at highest risk for invasive fungal infection, patients with severe pneumonia due to influenza, and ...
- Toowoomba teen diagnosed with leukaemia after tonsillitis check-upon October 4, 2020 at 8:59 pm
Naomi Ballard, 17, came down with a sore throat while visiting her Aunt in Roma last week and decided to book a doctors appointment.
- New oral treatment option for aggressive blood cancer, AMLon October 2, 2020 at 2:38 pm
WAUSAU, Wis. (WSAW) - September was Blood Cancer Awareness Month, a time to recognize and raise awareness for this diverse group of diseases, including acute myeloid leukemia, or AML, which is one of ...
- First man to be cured of HIV dies after leukaemia returnson September 30, 2020 at 4:09 am
Timothy Ray Brown has passed away after battling leukaemia for five months, his partner said on Facebook. The American was the first known HIV patient to be cured after extensive treatment in Berlin ...
- Acute Lymphocytic Leukemia Market to 2030 - Insight, Epidemiology and Forecast to 2030 - ResearchAndMarkets.comon September 26, 2020 at 7:10 am
Market Insight, Epidemiology and Forecast to 2030" report has been added to ResearchAndMarkets.com's offering. This report delivers an in-depth understanding of the ALL, historical and forecasted ...
- TikTok mum, 34, battling leukaemia diagnosed with COVIDon September 26, 2020 at 1:48 am
Tia Bee Mele Stokes was diagnosed with leukaemia in April and became an online sensation for filming herself dancing in her hospital room.
via Bing News